AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Hongli Group Inc.
Video analysis: HLP
All videosNo video analysis for this stock yet. Request one from our team.
News: HLP
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
Helus Pharma has built a proprietary psychedelic pipeline that currently spans MDD and GAD. The company has two clinical-stage assets and a broader serotonergic discovery platform. Early HLP003 (oral psilocin) and HLP004 (IM DMT) data suggest efficacy and durability when used as adjunctive therapies, although this comes from small trials. Helus is conducting a phase III trial for HLP003, which could validate its clinical profile and reduce the valuation discount relative to peers.
Hongli Group Inc. Announces Compliance with Nasdaq Minimum Bid Price Requirement
WEIFANG, China, Aug. 12, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on August 7, 2026, it received a notification letter from Nasdaq Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), dated August 7, 2026, stating that the Company has regained compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). Nasdaq made this determination of compliance after the closing bid price of the Company's Class A ordinary shares ("Class A Ordinary Shares") has been at $1.00 per share or greater for the last 10 consecutive business days from July 24, 2026 to August 6, 2026.
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 2026 1,2 HLP003 previously granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (“FDA”) HLP003 Phase 2 data demonstrated durable efficacy, with a mean ~23-point reduction in Montgomery-Asberg Depression Rating Scale (“MADRS”) score from baseline 12 months after two 16 mg doses administered three weeks apart, and 100% response and 71% remission rates based on a MADRS benchmark of ≤10, with remission rising to 100% using more recent peer-study benchmarks of ≤12 3 , 4 This news release constitutes a “designated news release” for the purpose of the Company's prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025. NEW YORK and TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”) a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that it has completed enrollment in its APPROACH Phase 3 pivotal study of HLP003 in patients living with Major Depressive Disorder (“MDD”).
Helus Pharma: APPROACHing Inflection: Pivotal Readout Sets Up Asymmetric Upside
I initiate coverage of Helus Pharma with a speculative Buy, citing an attractive high-risk/high-reward setup ahead of the pivotal Phase 3 APPROACH readout in Q4 2026. HELP's lead asset HLP003, an oral deuterated psilocin analog for adjunctive MDD, shows compelling Phase 2 efficacy, FDA Breakthrough Therapy Designation, and a differentiated clinical profile. Current valuation (~$269M EV, ~$207M pro forma cash) under-credits the probability-weighted value of HLP003, with a risk-adjusted implied EV of ~$1.5B if Phase 3 succeeds.
Hongli Group Inc. Receives Nasdaq Notice Regarding Minimum Bid Price Deficiency
WEIFANG, China, July 9, 2026 /PRNewswire/ -- Hongli Group Inc. (the "Company") (Nasdaq: HLP), a cold roll formed steel profile manufacturer, today announced that on July 2, 2026, it received a deficiency letter (the "Notice") from the Nasdaq Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq"). The Notice informed the Company that, based upon the closing bid price of the Company's Class A ordinary shares ("Class A Ordinary Shares") over the 30 consecutive business day period between May 19, 2026 and July 1, 2026, the Company is not in compliance with the requirement to maintain a minimum bid price of $1.00 per Class A Ordinary Share for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement").
Hongli Group Inc. Entered into Strategic Non-Binding MOU with Sidus Energy Storage, Inc. to Explore Potential Advanced Battery Manufacturing Collaboration
Proposed Partnership Supports the Company's ongoing Strategic Shift Toward Clean Energy and Energy Storage Solutions WEIFANG, China, June 15, 2026 /PRNewswire/ -- Hongli Group Inc. (Nasdaq: HLP) (the "Company" or "Hongli Group"), a cold roll formed steel profile manufacturer, today announced that it has entered into a non-binding Memorandum of Understanding ("MOU") with Sidus Energy Storage, Inc. ("Sidus"), a California-based battery technology company, to explore a potential strategic manufacturing collaboration relating to advanced battery and energy storage products targeting the high-growth North American and European energy storage markets. This proposed collaboration represents a further step in Hongli Group's clean energy evaluation.
Similar companies
-
Ascent Industries Co.
ACNT
·
NASDAQ
Compare
-
Flexible Solutions International, Inc.
FSI
·
New York Stock Exchange Arca
Compare
-
Westwater Resources, Inc.
WWR
·
New York Stock Exchange Arca
Compare
-
Bioceres Crop Solutions Corp.
BIOX
·
NASDAQ
Compare
-
Fury Gold Mines Limited
FURY
·
New York Stock Exchange Arca
Compare
-
5E Advanced Materials Inc.
FEAM
·
NASDAQ
Compare